0001725160-24-000043.txt : 20240212
0001725160-24-000043.hdr.sgml : 20240212
20240212202244
ACCESSION NUMBER: 0001725160-24-000043
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240212
FILED AS OF DATE: 20240212
DATE AS OF CHANGE: 20240212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Epperly Melissa B,
CENTRAL INDEX KEY: 0001807359
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39263
FILM NUMBER: 24622201
MAIL ADDRESS:
STREET 1: C/O ZENTALIS PHARMACEUTICALS, INC.
STREET 2: 530 SEVENTH AVENUE, SUITE 2201
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001725160
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 823607803
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1359 BROADWAY, SUITE 801
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: (212) 433-3791
MAIL ADDRESS:
STREET 1: 1359 BROADWAY, SUITE 801
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20200107
FORMER COMPANY:
FORMER CONFORMED NAME: Zeno Pharma, LLC
DATE OF NAME CHANGE: 20171212
4
1
wk-form4_1707787354.xml
FORM 4
X0508
4
2024-02-12
0
0001725160
Zentalis Pharmaceuticals, Inc.
ZNTL
0001807359
Epperly Melissa B,
C/O ZENTALIS PHARMACEUTICALS, INC.
1359 BROADWAY, SUITE 801
NEW YORK
NY
10018
0
1
0
0
Chief Financial Officer
0
Common Stock
2024-02-12
4
S
0
2573
11.44
D
451449
D
Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person.
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.29 to $11.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
By: /s/ Melissa B. Epperly
2024-02-12